Company Description
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression.
It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing.
The company was incorporated in 2017 and is headquartered in Alameda, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jul 24, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 89 |
| CEO | Benjamin Oakes |
Contact Details
Address: 1150 Marina Village Pkwy Alameda, California 94501 United States | |
| Phone | 510 626 8587 |
| Website | scribetx.com |
Stock Details
| Ticker Symbol | SCTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 1853921 |
| CUSIP Number | 811033109 |
| ISIN Number | US8110331092 |
| Employer ID | 82-2157847 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Benjamin L. Oakes, Ph.D. | President, Chief Executive Officer and Director |
| Svetlana Lucas, Ph.D. | Chief Business Officer |
| David L. Parrot, M.B.A. | Chief Financial Officer |
| James Watson, M.B.A. | Director |
| Behzad Aghazadeh, Ph.D. | Director |
| Carl L. Gordon, Ph.D., CFA | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 30, 2026 | SCHEDULE 13D | Filing |
| Jul 30, 2026 | SCHEDULE 13D | Filing |
| Jul 29, 2026 | SCHEDULE 13D | Filing |
| Jul 27, 2026 | 8-K | Current Report |
| Jul 27, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 27, 2026 | 424B4 | Prospectus |
| Jul 24, 2026 | FWP | Free Writing Prospectus |
| Jul 23, 2026 | EFFECT | Notice of Effectiveness |
| Jul 23, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Jul 22, 2026 | CERT | Certification by an exchange approving securities for listing |